ProfileGDS5678 / 1447772_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 44% 43% 43% 45% 44% 43% 44% 49% 46% 46% 44% 41% 44% 50% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0762844
GSM967853U87-EV human glioblastoma xenograft - Control 23.0013943
GSM967854U87-EV human glioblastoma xenograft - Control 32.9855643
GSM967855U87-EV human glioblastoma xenograft - Control 42.9903245
GSM967856U87-EV human glioblastoma xenograft - Control 52.9862144
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0917543
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0986644
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1630149
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0572146
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0497246
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0283844
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9176641
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0440744
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1826450